Calderon Gerardo Familiar
Known title: Pres Advanced Performance MatCIK: 0001971603
Calderon Gerardo Familiar's purchase track record
Calderon Gerardo Familiar has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/12/2026 | CC | $30K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CC | ▲ Buy | Open Market | 1,935 | $30K | 8/12/2026 | View on chart |
| CC | ▼ Sell | Tax Withholding | 943 | $16K | 8/1/2026 | View on chart |
| CC | ▲ Buy | Grant | 25,708 | $0 | 3/2/2026 | View on chart |
| CC | ▼ Sell | Tax Withholding | 2,635 | $48K | 3/1/2026 | View on chart |
| CC | ▼ Sell | Tax Withholding | 1,294 | $20K | 9/1/2025 | View on chart |
| CC | ▼ Sell | Tax Withholding | 923 | $11K | 8/1/2025 | View on chart |
| CC | ▲ Buy | Grant | 13,437 | $0 | 3/3/2025 | View on chart |
| CC | ▼ Sell | Tax Withholding | 1,311 | $20K | 3/1/2025 | View on chart |
| CC | ▼ Sell | Tax Withholding | 876 | $20K | 8/1/2024 | View on chart |
| CC | ▲ Buy | Grant | 5,909 | $0 | 5/8/2024 | View on chart |
| CC | ▼ Sell | Tax Withholding | 747 | $16K | 3/1/2024 | View on chart |
| CC | ▲ Buy | Grant | 7,867 | $0 | 8/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Chemours Q2 Earnings Call and UBS Price Target Cut
Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.
Chemours Q2 Earnings Call and UBS Price Target Cut. Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.